SNGX - Why Is Rare Disease Focused Soligenix Stock Soaring Today? | Benzinga
Soligenix Inc (NASDAQ: SNGX) announced a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.
The vaccine candidate has been previously demonstrated to be stable to high-temperature storage for at least two years at 40 degrees Celsius (104 degrees Fahrenheit).
Currently, there are no approved ...